Home World News FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung... World News FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 663 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Young Mom Of Two Survived Breast Cancer, Heart Failure, And Two... January 16, 2020 Patient Guide on Bone Health in Cancer Now Available Also in French January 19, 2026 EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of... October 12, 2023 Classmates Surprise Badly Bullied Teen After Weeks Of Planning: ‘You Deserve... March 29, 2019 Load more HOT NEWS Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly... ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... ESMO Shares Recommendations to Support Cancer Research and Clinical Trials in...
